Neovascular age-related macular degeneration+1
RecruitingStudy of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration
Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration
- Disease:Neovascular age-related macular degenerationAge-related macular degeneration
- Substances:Ranibizumab
Spain- Participants:18–64 years · 65+ years
- Substances:Ranibizumab
- Sponsor:F. Hoffmann-La Roche AG










